Skip to main content

Table 2 Summary baseline characteristics of the eligible study population

From: Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care

Baseline characteristics

Study population n = 678

Sex: male n (%)

313 (46.2)

Age: median (IQR)

46 (26, 60)

BMI, median (IQR)

26.0 (22.9, 30.6)

Rhinitis diagnosis or therapy, n (%)

305 (45.0)

Smoking status, n (%)

Current Smoker

40 (5.9)

 

Ex-smoker

145 (21.4)

 

Non-smoker

477 (70.4)

Exacerbations, n (%)

0

551 (81.3)

 

1

83 (12.2)

 

≥2

44 (6.5)

SABA dose (mcg), n (%)

1-100

121 (17.8)

 

101-200

132 (19.5)

 

201-400

94 (13.9)

 

401+

47 (6.9)

Average ICS Daily dose, (mcg) BDP-equivalent dose, n (%)

None

304 (44.8)

 

1-100

67 (9.9)

 

101-200

106 (15.6)

 

201-400

101 (14.9)

 

401+

100 (14.7)

Asthma therapy, n (%)

None

193 (28.5)

 

SABA

101 (14.9)

 

±SABA

LTRA

8 (1.2%)

  

ICS

182 (26.8)

  

ICS + LABA

136 (20.1)

  

ICS + LAMA

1 (0.1)

 

±SAMA

ICS + LABA + LAMA

5 (0.7)

  

ICS + LTRA

8 (1.2)

  

ICS + LABA + LTRA

42 (6.2)

 

Other

2 (0.3)